関連する実験動画
Updated: Sep 9, 2025

09:59
Preparation of Exosomes for siRNA Delivery to Cancer Cells
Published on: December 5, 2018
25.4K
免疫細胞から得られたCAR-エクソソーム:腫瘍免疫療法の障害を克服するナノスケールの先駆者
Xiaoyan Zhao1, Bin Zhao2, Yan Sun3
1Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in immunology
|September 4, 2025
まとめ
化学抗原受容体 (CAR) - エクソソームは,固体腫瘍に対する新しい細胞フリー療法を提供し,従来のCAR細胞療法の限界を克服します. これらのエンジニアリングされたエクソソームは より安全で効果的ながん免疫療法に 期待されています
科学分野:
- 免疫学
- ナノ医療
- 腫瘍学
背景:
- 化学抗原受容体 (CAR) による細胞治療は,血液がんに対して有効ですが,毒性や腫瘍の不十分な浸透など,固体腫瘍では課題に直面しています.
- 固体腫瘍におけるCAR-T,CAR-NK,CAR-M細胞治療の限界は,革新的なアプローチを必要とします.
研究 の 目的:
- 固体腫瘍におけるCAR細胞療法に関連する課題を検討する.
- 次の世代のがん免疫療法プラットフォームとしてCAR-Exosomesの可能性を強調します.
- CAR-Exosomesの最近の進歩と臨床翻訳戦略を要約する.
主な方法:
- CAR細胞療法とCAR-Exosomesに関する現在の文献の体系的なレビュー.
- CAR-エクソソームの特性,標的化メカニズム,治療経路の分析
- CAR-Exosomesのバイオセーフティとエンジニアリング戦略の評価
主要な成果:
- CAR-エクソソームは,親 CAR 細胞から腫瘍を標的とする能力を継承する.
- CAR-エクソソームは,低免疫性,強化された組織浸透性,および薬物負荷能力などの利点を提供します.
- 最近の進歩は,CAR-Exosomeの分子特性,ターゲティング,殺戮経路,安全性,工学をカバーしています.
結論:
- CAR-Exosomesは,固体腫瘍に対する有望な細胞フリー治療戦略であり,従来のCAR細胞治療の限界に対処しています.
- ナノ医療と細胞治療を統合した CAR-Exosomesは 癌の免疫療法に より安全で効果的なアプローチを 提供しています
- CAR-Exosomesの潜在力を最大限発揮するには,さらなる研究と臨床翻訳戦略が不可欠です.
さらに関連する動画
関連する概念動画
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Overview of Exosomes
2.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Mesenchymal Stem Cells
5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K

